Artogistan Injection 100mg / 2ml amp ml 10 units


Artogistan Injection 100mg / 2ml amp ml 10 units



Active substance:
1 ml of the preparation contains:
Sodium chondroitin sulfate 100 mg.
Benzyl alcohol 9 mg
Sodium bisulfite 1 mg 1 M sodium hydroxide solution to pH 6.0 – 7.5
Water for injections to 1 mL.
Transparent or slightly opalescent, colorless or slightly colored liquid with an odor of benzyl alcohol.
Product form:
Solution for intramuscular administration of 100 mg / ml.
1 or 2 ml vial of clear or colored glass of hydrolytic class 1 or the NS-3. 5 or 10 vials in blisters of polyvinyl chloride or polyethylene terephthalate film with a polymer film or lacquered aluminum foil, or without a polymeric film and aluminum foil patent or in the form of cardboard with cells for stacking ampoules.
1 the contour cellular packaging made of cardboard or form with 10 ampoules or blisters 2 or shapes from a cardboard of 5 ampoules together with instructions for use and a lancet ampulnam or without a pack of cardboard.
– increased sensitivity to the drug or its components; – bleeding, a tendency to bleeding; – thrombophlebitis; – Children up to age 18 years (effectiveness and safety have been established).
100 mg / ml
Degenerative-dystrophic diseases of joints and spine: osteoarthritis and osteochondrosis.
To accelerate callus formation in fractures.
Interaction with other drugs
May increase the action of indirect anticoagulants, antiplatelet agents, fibrinolytics.
Currently, cases of overdose of chondroitin sulfate have been reported.
pharmachologic effect
Pharmacological group:
Tissue repair promoter.
ATC code: M01AH25.
Has hondrostimuliruyuschee, regenerating, anti-inflammatory and analgesic effect. Chondroitin sulfate is involved in the construction of the basic substance of cartilage and bone. Has chondroprotective properties, increases metabolism in hyaline and fibrous cartilage, subchondral bone; inhibits enzymes that cause degeneration (destruction) of the articular cartilage; It stimulates the production of proteoglycans by chondrocytes. Helps to reduce emissions in the synovial fluid of mediators of inflammation and pain factors, suppresses secretion of leukotrienes and prostaglandins. Slows bone resorption and reducing calcium loss, accelerates bone regeneration.
Chondroitin sulfate slows the progression of osteoarthritis and osteoarthritis.
Promotes restoration of the joint capsule and cartilage surfaces of the joints, prevents the collapse of the connective tissue, normalizes the production of joint fluid.
In applying the drug reduced pain and improved mobility of the affected joints, the therapeutic effect lasts for a long time after the end of therapy. In the treatment of degenerative changes of the joints accompanied by secondary synovitis, the effect has been observed in 2-3 weeks from the date of commencement of the course.
With structural similarity to heparin may potentially inhibit the formation of fibrin clots in synovial and subchondral microvasculature.
30 minutes after intramuscular administration is detected in significant concentrations in the blood; after 15 minutes – in the synovial fluid. The maximum plasma concentration (Cmax) is achieved after 1 hour, then the drug concentration decreases gradually within 2 days.
Accumulates mostly in the cartilaginous tissue (maximum concentration in the articular cartilage is reached after 48 hours); synovial membrane is not a barrier to penetration of the drug into the joint cavity. Excreted by the kidneys.
Pregnancy and breast-feeding
Do not use the drug during pregnancy. During treatment, breast-feeding should be discontinued due to lack of data.
Conditions of supply of pharmacies
On prescription.
side effects
Allergic reactions (pruritus, rash, erythema, urticaria, dermatitis, edema); bleeding at the injection site.
special instructions
In a joint application of the drug with indirect anticoagulants, antiplatelet agents, fibrinolytics require more frequent monitoring of blood coagulation parameters.
In the case of allergic reactions or appearance of hemorrhage treatment should be discontinued.
To achieve the necessary stable clinical effect for at least 25 injections of the drug, but the effect is retained during prolonged several months after treatment. For the prevention of relapse show repeated courses of treatment.
Effects on ability to drive vehicles and mechanisms:
The drug has no effect on the ability to drive, use machines and engage in other activities that require increased attention and psychomotor speed reactions.
Storage conditions
At a temperature not exceeding 25 C. Keep out of reach of children.
Dosing and Administration
Intramuscularly, 100 mg every other day. With good tolerance dose increased to 200 mg, starting from the fourth injection. The course of treatment – 25-35 injections. If necessary, after 6 months may conduct re-treatment.
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg

Grotex Ltd.

There are no reviews yet.

Add your review